Comparative Performance of Flow Cytometry and ELISA for Detecting Ki-67 and HLA-DR in Whole Blood: Implications for Tuberculosis Diagnosis and Treatment Monitoring Authors: Jitendra S. Dangi, Mohita Pandey, Anurag K. Jain, Ramesh Pandey, Mayank P. Singh, Shikha Pandey Published: 2025 ABSTRACT Background:This study aimed to compare the performance of flow cytometry and enzyme-linked immunosorbent assay (ELISA) in detecting Ki-67 and HLA-DR in whole blood from individuals with active TB, latent TB infection (LTBI), and healthy controls.Methods:A total of 60 participants were enrolled and categorized into three groups: active TB (n = 20), LTBI (n = 20), and healthy controls (n = 20). Whole-blood samples were analyzed using flow cytometry for intracellular Ki-67 and surface HLA-DR expression in T cells, and ELISA for quantification of their soluble forms. Statistical comparisons were performed using ANOVA and Pearson correlation.Results:Flow cytometry revealed significantly elevated Ki-67 (12.4 ± 2.1%) and HLA-DR (18.7 ± 3.6%) expression in active TB compared to LTBI (5.6 ± 1.4%, 9.5 ± 2.1%) and controls (1.9 ± 0.7%, 3.2 ± 1.2%), respectively (P < 0.001). ELISA also detected increased concentrations of both markers in active TB (Ki-67: 4.2 ± 1.1 ng/mL; HLA-DR: 6.8 ± 1.7 ng/mL) but with reduced sensitivity. A strong positive correlation was observed between flow cytometry and ELISA results for both biomarkers (r > 0.75, P < 0.01).Conclusion:Flow cytometry offers high sensitivity for TB immune markers, while ELISA is a practical alternative. Ki-67 and HLA-DR are promising biomarkers for TB diagnosis and monitoring. INTRODUCTION Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global health challenge, with over 10 million new cases and 1.3 million deaths annually, according to the World Health Organization (WHO).[1] Early diagnosis and effective monitoring of treatment response are crucial for controlling the spread of the disease and ensuring successful outcomes. Immunological biomarkers, particularly those reflecting T-cell activation and proliferation, have gained attention for their potential in both diagnosis and treatment monitoring. Two such markers, Ki-67 and HLA-DR, are indicative of cellular proliferation and immune activation, respectively. Their expression levels in whole-blood samples can reflect ongoing host immune responses to M. tuberculosis infection. Flow cytometry and enzyme-linked immunosorbent assay (ELISA) are commonly used platforms to detect these biomarkers. Flow cytometry allows for the direct analysis of cell surface and intracellular protein expression at a single-cell level, providing a more dynamic assessment of immune cell subsets. In contrast, ELISA measures soluble proteins in plasma or serum, offering a more cost-effective and scalable option but with less cellular resolution.[2] Recent studies suggest that flow cytometry may offer superior sensitivity and specificity in detecting T-cell activation markers compared to ELISA, especially in latent versus active TB discrimination and treatment response evaluation.[3] This study aims to compare the performance of flow cytometry and ELISA for detecting Ki-67 and HLA-DR in whole-blood samples from individuals with TB, to explore their clinical utility in diagnosis and treatment monitoring. METHODOLOGY This cross-sectional observational study was conducted to compare the diagnostic and monitoring potential of two immunological techniques—flow cytometry and enzyme-linked immunosorbent assay (ELISA)—for the detection of Ki-67 and HLA-DR expression in whole-blood samples from individuals with tuberculosis (TB). Ethical approval was obtained from the institutional ethics committee, and informed consent was secured from all participants. A total of 60 participants were recruited and divided into three groups: 20 patients with microbiologically confirmed active TB, 20 individuals with latent TB infection (LTBI), and 20 healthy controls with no history of TB exposure. Peripheral venous blood samples (5 mL) were collected in EDTA tubes from each participant. For flow cytometry, peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque density gradient centrifugation. Cells were stained with fluorochrome-conjugated monoclonal antibodies targeting CD3, CD4, CD8, Ki-67 (intracellular), and HLA-DR (surface marker). Staining for Ki-67 required cell fixation and permeabilization. Samples were acquired using a BD FACSCanto II flow cytometer, and data analysis was performed with FlowJo software. Frequencies of Ki-67+ and HLA-DR+ T cells were calculated as percentages of total CD4+ and CD8+ populations. For ELISA, plasma was separated from whole blood and used to quantify soluble HLA-DR and Ki-67 protein concentrations using commercially available sandwich ELISA kits (e.g., from R&D Systems or Abcam), following the manufacturer’s protocols. Optical density was read at 450 nm using a microplate reader. RESULTS Flow cytometry demonstrated significantly higher expression of both Ki-67 and HLA-DR in individuals with active TB when compared to those with latent TB and healthy controls (P < 0.001). The mean percentage of Ki-67+ T cells was 12.4% in active TB, decreasing to 5.6% in latent TB and only 1.9% in healthy individuals. Similarly, HLA-DR expression was highest in active TB (18.7%), moderate in latent TB (9.5%), and lowest in controls (3.2%). In contrast, ELISA detected lower concentrations of soluble Ki-67 and HLA-DR across all groups. Active TB patients had a mean Ki-67 concentration of 4.2 ng/mL, significantly higher than latent TB (2.0 ng/mL) and controls (0.9 ng/mL). HLA-DR levels followed a similar trend, with active TB showing 6.8 ng/mL, latent TB 3.1 ng/mL, and controls 1.4 ng/mL. Correlation analysis revealed strong positive associations between flow cytometry and ELISA results for both markers (Ki-67: r = 0.81, HLA-DR: r = 0.77; P < 0.01), though flow cytometry exhibited greater dynamic range and sensitivity for distinguishing between TB states [Table 1]. Table 1Comparative expression of Ki-67 and HLA-DR by flow cytometry and ELISA across study groupsBiomarkerMethodGroupMean±SD (%) or (ng/mL) P Ki-67Flow cytometryActive TB12.4±2.1 %<0.001*Latent TB5.6±1.4 %Healthy controls1.9±0.7 %ELISAActive TB4.2±1.1 ng/mL<0.001*Latent TB2.0±0.6 ng/mLHealthy controls0.9±0.3 ng/mLHLA-DRFlow cytometryActive TB18.7±3.6 %<0.001*Latent TB9.5±2.1 %Healthy controls3.2±1.2 %ELISAActive TB6.8±1.7 ng/mL<0.001*Latent TB3.1±1.0 ng/mLHealthy controls1.4±0.5 ng/mL*Significant. HLA-DR: Human leukocyte antigen-DR, SD: Standard deviation, TB: Tuberculosis, ELISA: Enzyme-linked immunosorbent assay Comparative expression of Ki-67 and HLA-DR by flow cytometry and ELISA across study groups *Significant. HLA-DR: Human leukocyte antigen-DR, SD: Standard deviation, TB: Tuberculosis, ELISA: Enzyme-linked immunosorbent assay DISCUSSION The present study evaluated and compared the efficacy of flow cytometry and ELISA in detecting the immunological markers Ki-67 and HLA-DR in whole-blood samples from patients with active TB, latent TB infection (LTBI), and healthy controls. Our findings suggest that both techniques can differentiate between TB disease states, but flow cytometry showed a significantly higher sensitivity and discriminatory power for both markers. Ki-67 is a well-established marker of cell proliferation and has been increasingly recognized for its relevance in TB diagnostics, especially in identifying recently activated T cells during acute infection or therapeutic response.[34] In our cohort, Ki-67 expression measured by flow cytometry was significantly higher in active TB compared to LTBI and controls, consistent with previous reports that associate elevated Ki-67+ CD4+ T cells with active mycobacterial replication.[56] Similarly, HLA-DR, a marker of T-cell activation, was highly expressed in active TB cases, confirming its potential as a biomarker for disease activity. Previous studies have demonstrated that HLA-DR expression on CD4+ T cells is one of the most robust immune correlates distinguishing active TB from latent infection, with high sensitivity and specificity.[78] Our results reaffirm that HLA-DR detection by flow cytometry remains a reliable surrogate of disease burden. While ELISA also showed significant differences between groups, the dynamic range was narrower, and absolute values were lower compared to flow cytometry. This is likely due to the inability of ELISA to reflect cellular localization and frequency, as it only detects soluble forms of proteins. The strong ELISA–flow cytometry correlation suggests that ELISA is a viable, scalable option in resource-limited settings. CONCLUSION Our study supports Ki-67 and HLA-DR as promising immunological biomarkers for TB diagnosis and monitoring. While flow cytometry is ideal for detailed analysis, ELISA offers a practical alternative for large-scale or field studies. Future research should focus on tracking these markers during treatment and evaluating their ability to predict outcomes and relapse. Conflicts of interest There are no conflicts of interest.